BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) was upgraded by stock analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a note issued to investors on Tuesday. BMRN has ...

Though BioMarin’s portfolio comprises eight marketed products, its top line is likely to have been driven by key drugs Voxzogo, Naglazyme and Vimizim. Since its commercial launch in 2021 ...

BioMarin’s revenue largely comes from a few key products, notably Voxzogo and enzyme therapies. It has achieved strong growth through regulatory approvals and market expansion initiatives ...

Now moving over to our enzyme therapies. Global demand drove strong results across all of BioMarin's marketed products. Double-digit PALYNZIQ revenue growth in the quarter was the result of ...

BioMarin's has signed the first contract with ... 92% of patients still had no need to take prophylactic Factor VIII replacement products at that timepoint, reinforcing the durability of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.